Key Highlights

  • Net income was USD 7.2 million in the third quarter ended September 30, 2026, against a net loss of USD 3.5 million a year earlier, with GAAP Earnings of USD 0.07 per share and adjusted earnings of USD 0.26 per share.
  • Consolidated Revenue rose 5.0% to USD 272.0 million from USD 258.9 million, while system-wide revenue grew 7.7% and advanced procedure mix hit 31.8% consolidated and 38.2% system-wide.
  • Adjusted EBITDA increased to USD 62.6 million from USD 59.1 million, lifting the Margin to 23.0% from 22.8%, and interest expense fell to USD 15.7 million from USD 30.6 million.
  • Full-year adjusted EPS guidance was raised to USD 0.86 to USD 0.90 from USD 0.71 to USD 0.77, driven by a lower assumed effective tax rate, with the EBITDA range narrowed to USD 236 million to USD 240 million.

Lower Interest Costs Drive the Swing to Profit

Lumexa Imaging (NASDAQ:LMRI) reported third-quarter results on November 10, 2026. The profit swing came largely below the operating line, because income from operations actually slipped to USD 28.1 million from USD 30.3 million. General and administrative expense jumped to USD 30.0 million from USD 17.1 million, which management attributed to public company costs of USD 1.8 million and higher stock-based compensation of USD 12.3 million, tied to resetting legacy Equity plans around the IPO. Interest expense roughly halved after IPO proceeds repaid debt, and equity in earnings of unconsolidated affiliates rose to USD 22.8 million from USD 18.0 million.

Advanced Imaging Mix, Cash Flow and De Novo Openings

The company, which operates about 190 outpatient imaging centers, said advanced procedures such as MRI and CT, which management said reimburse three to four times more than routine scans, reached a record share of volume. Consolidated advanced procedures grew 7.9% to 200,600, and system-wide total procedures rose 4.0% to 1,049,491. Cash from operations was USD 34.8 million and free cash flow was USD 20.6 million against negative USD 1.8 million, a conversion of about 32.9% of adjusted EBITDA, management said. Cash stood at USD 90.0 million versus USD 58.8 million at year-end. Three new centers were opening in early November, toward a goal of 8 to 10 openings in 2026.

Guidance Shift: Steady Revenue, Narrower EBITDA, Higher Adjusted EPS

Revenue guidance of USD 1.045 billion to USD 1.097 billion was reiterated. Adjusted EBITDA guidance narrowed to USD 236 million to USD 240 million, keeping the USD 238 million midpoint, and the company said about USD 7 million of public company costs lowers 2026 growth at the midpoint from 7% to 4%. The higher adjusted EPS range reflects a lower tax rate, not stronger operations. Long-term debt, less current maturities, was USD 821.5 million, so interest and Leverage remain central. Management also said on the call that it expects at least 30% free cash flow conversion for the year and a limited effect from a federal site-neutral payment rule on 2027 reimbursement.

Where Things Stand

Mainly through lower interest and equity earnings, not faster growth. Lumexa Imaging (NASDAQ:LMRI) grew consolidated revenue 5.0%, but Operating Income fell as general and administrative costs rose, while interest expense dropped by about USD 14.9 million (calculated) and equity earnings added USD 4.9 million (calculated) to the result. The guidance raise is on adjusted EPS only, tied to taxes. Next markers are the full-year results, the three new center openings, further health system partnerships and whether free cash flow conversion holds above the 30% management floor.